SC Biz News


Subscribe to Our Digital Newsletters

SCRA invests in Greenville cancer research firm Kiyatec

  • cmsteam
Print Story
  • Share

Staff Report
Published Nov. 11, 2015

SCRA has made an investment in Kiyatec Inc., which operates alongside Greenville Health Systems Institute for Translational Oncology Research. SCRA’s Stage 2 program provides investments up to $5 million in South Carolina-based technology companies.

Kiyatec, started in 2005 by Matthew Gevaert and David Orr based on research Orr started at Clemson University, offers cell-based drug response profiling services for pharmaceutical and biotech companies using Kiyatec’s three-dimensional cell culture technology platform.

Previous coverage:

“This strategic investment will enable Kiyatec to accelerate the growth of the company’s preclinical services business and further develop its future clinical services offering,” said Martin Ettlemyer, SCRA vice president of strategic investments and manager of the Stage 2 program portfolio.

SCRA CEO Bill Mahoney said the Stage 2 program “uses retained earnings from SCRA’s core R&D operations to fulfill our mission to grow South Carolina’s high-tech landscape.”

“We have a long history with Kiyatec, first making an investment through our SC Launch program in 2008 and making several subsequent investments since,” Mahoney said.

  • Share
Write a Comment